Exagen to Announce Second Quarter Financial Results on July 28, 2020

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) will announce financial results for Q2 2020 on July 28, 2020, before market open. The call, hosted by CEO Ron Rocca and CFO Kamal Adawi, is set for 8:00 AM ET (5:00 AM PT). Interested parties can join via phone or webcast through Exagen's investor relations site. A replay will be available until August 4, 2020. Exagen focuses on enhancing care for autoimmune disease patients through advanced testing products, optimizing diagnosis, and treatment strategies.

Positive

• Upcoming financial results release could provide insights into growth and performance.
• Exagen specializes in innovative testing products for autoimmune diseases, potentially positioning it well for market demand.

Negative

• None.

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended June 30, 2020 before the market opens on Tuesday, July 28, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:00 AM Eastern Time (5:00 AM Pacific Time).

Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international).  Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/

A replay of the conference call will be available until Tuesday, August 4, 2020 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13706731.  Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

CONTACTS:

Investors

Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838

Company Contact

Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514

FAQ

When will Exagen announce its financial results for Q2 2020?

Exagen will announce its financial results for Q2 2020 on July 28, 2020, before market open.

What time is the Exagen conference call scheduled?

The conference call is scheduled for 8:00 AM ET (5:00 AM PT) on July 28, 2020.

How can I access the Exagen Q2 2020 conference call?

You can access the conference call by dialing (877) 407-3982 for U.S. or (201) 493-6780 for international participants or via webcast on Exagen's investor relations website.

Is there a replay available for the Exagen conference call?

Yes, a replay of the conference call will be available until August 4, 2020.

What is Exagen's focus in the healthcare sector?

Exagen is dedicated to transforming care for patients with autoimmune diseases through innovative testing products and optimizing diagnostic interventions.